Juntendo Medical Journal, 2025 Reviews Juntendo Medical Journal 2025 Pancreatic β-cell Dysfunction and Diabetes Hitoshi IIDA, Hirotaka WATADA TEL: +81-3-5802-1579 〔Received FAX: +81-3-3813-5996 Jan. 21, 2025〕 〔Accepted E-mail: iida_myb@juntendo.ac.jp Feb. 10, 2025〕 J-STAGE Advance published date: May. 9, 2025 Copyright © 2025 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ25-0001-R 1 Iida H, Watada H: Insights into pancreatic β-cell dysfunction and diabetes pathogenesis tissue through its hormonal actions. Chronic overnutrition and physical inactivity can cause insulin resistance due to metabolic abnormal obesity. Pancreatic β-cells compensate it by hypersecreting insulin, but prolonged exposure of insulin resistance state leads to β-cell dysfunction and hyperglycemia5). Most patients with T2D in Western populations are obese, with 89% having a BMI ≥ 25 kg/m2 6), while Japanese patients have an average BMI < 25 kg/m2 7). Asians have higher insulin sensitivity but lower insulin secretion than Caucasians8), predisposing them to T2D at lower obesity levels. As obesity and insulin resistance progress, insulin demand increases and β-cell function declines, leading to reduced insulin supply and rising blood glucose levels. Thus, understanding the mechanisms of pancreatic β-cell dysfunction is crucial for early diabetes detection and intervention. Physiology of pancreatic β-cells Structure of the islets of Langerhans The pancreas maintains digestive and metabolic balance by secreting various enzymes and hormones. In adult mammals, it consists of exocrine and endocrine cells. Exocrine cells, primarily composed of acinar cells, produce digestive enzymes, while endocrine cells form the islets of Langerhans, which regulate glucose homeostasis through hormone secretion. The human pancreas has about one million islets, with hormone-producing cells classified into five types: • α-Cells secrete glucagon. • β-Cells secrete insulin and amylin. • δ-Cells secrete somatostatin. • γ-Cells secrete pancreatic polypeptide. • ε-Cells secrete ghrelin, rare. These hormones are crucial for metabolic regulation and homeostasis9). β-cells, which constitute 65-80% of islet cells, exclusively synthesize insulin. “β-cell mass” denotes the total β-cells in the pancreas, approximately 1 g in humans, predominantly located in the pancreatic tail, making in vivo visualization and quantification difficult. Current βcell mass assessments rely on pathological analyses of pancreatic tissues from surgery or autopsy10, 11). A study comparing β-cell mass in obese, non-diabetic Japanese individuals (mean BMI 28.5 kg/m2) and non-obese individuals (mean BMI 20.4 kg/m2) 2 found no significant increase in β-cell mass in Japanese individuals12). In contrast, studies on Caucasians showed significant increase in β-cell mass with obesity13). This suggests that β-cell regeneration capacity in Japanese individuals may be lower than in Caucasians, influenced by genetic and environmental factors, contributing to the lower BMI manifestation of T2D in Asians compared to Western populations14). Additionally, pathological studies indicate a significant reduction in β-cell mass in patients with T2D. Butler et al. found β-cell mass in lean patients with T2D reduced by about 40%, and in obese patients with T2D, by about 65% compared to non-diabetic controls matched for age and BMI15). These findings highlight the crucial role of β-cell mass in T2D pathophysiology and the importance of understanding β-cell dynamics in the progression of diabetes. Insulin biosynthesis Insulin biosynthesis begins with the expression of the insulin gene, which comprises three exons and two introns. The promoter region contains A, C, E, Z, and CRE elements crucial for β-cellspecific localization and serve as binding sites for pancreatic β-cell transcription factors, thereby regulating gene expression. These binding sites are within the -400 bp upstream of the transcription start site. Key transcriptional regulators such as PDX1, BETA2/NeuroD, and MafA drive the expression of preproinsulin mRNA, which ribosomes subsequently translate16). Preproinsulin mRNA, with a long half-life, becomes 2-3 times more stable in glucose-stimulated β-cells than in non-stimulated conditions. Its expression is acutely regulated by drugs, hormones, nutrients, particularly glucose, and its metabolites. This enhanced mRNA stability and cap-independent translation enable β-cells to meet sudden insulin demands during postprandial hyperglycemia17). Once translocated into the endoplasmic reticulum (ER) lumen, preproinsulin’s signal peptide is cleaved, and it undergoes oxidative folding and disulfide bond formation, facilitated by protein disulfide isomerase (PDI) family members, with ERO1α/β regenerating PDI. Ca2+-dependent chaperones like BiP assist in proinsulin folding. Misfolded proinsulin is identified and removed by ER-associated degradation (ERAD) and ER-phagy18). Juntendo Medical Journal, 2025 Proinsulin and processing enzymes are transported from the ER to the Golgi apparatus via COPII-mediated vesicular transport. In Golgi, proinsulin is packaged into secretory granules, with chromogranin A and B supporting protein condensation within immature granules. These granules bud from the Golgi and mature through microtubuledependent processes, involving granule ion regulation, secretory responsiveness acquisition, proinsulin processing, protein condensation, and granule membrane stabilization19). Proinsulin conversion to mature insulin occurs in two steps. C-peptide cleavage at the B and A chain junctions, primarily involving PC1/3 in human β-cells and PC1/3 and PC2 in rodent β-cells. For this process, granule acidification and high Ca2+ concentrations are essential. Carboxypeptidase E (CPE), requiring Zn2+, further processes insulin. The mature insulin forms Zn2+-centered hexamers, stored in the form of dense-core granules for release20). Insulin secretion Pancreatic β-cells possess a glucose-sensing mechanism that dynamically regulates insulin secretion to maintain blood glucose levels within the normal range. The rate of glucose metabolism is a critical determinant of the magnitude of the insulin secretory response as insulin secretion is regulated by ATP production and other metabolic coupling factors. Glucose is transported into β-cells via glucose transporters and is subsequently phosphorylated to glucose-6-phosphate by glucokinase (GK), which acts as the rate-limiting enzyme of glycolysis. This reaction allows GK activity to respond to changes in the physiological level of glucose concentration, thereby modulating glucose metabolism and insulin secretion. Glucose is eventually metabolized to pyruvate, which enters the mitochondrial tricarboxylic acid (TCA) cycle and promotes ATP production. An increase in ATP triggers the closure of ATPsensitive potassium (KATP) channels, leading to membrane depolarization, which opens voltagedependent Ca2+ channels. The resulting influx of Ca2+ into the cytosol triggers exocytosis of insulin granules21). The primary physiological stimulus for insulin secretion is the postprandial increase in circulating glucose levels. Glucose-induced insulin secretion is mediated through two main pathways, ‘‘triggering’’ and ‘‘amplifying.” The triggering pathway involves the rapid rise in intracellular Ca2+ concentration due to ATP production during glucose metabolism, which induces the exocytosis of insulin granules. This pathway is responsible for the first phase of insulin secretion, which is initially rapid and sharp. The amplifying pathway, which follows the triggering pathway, controls the second phase of insulin secretion, which is prolonged insulin release over several hours postprandially. This pathway is activated through KATP channel-independent mechanisms with various intracellular metabolic pathways that modulate this second phase. The insulinotropic effects of GLP-1 receptor agonists enhance insulin secretion by promoting this second-phase response. In various types of diabetes, the impairment of these normal functions is a common pathological feature. The following chapter provides an overview of the different types of diabetes. Types of diabetes mellitus Diabetes mellitus manifests as a result of various etiologies and is broadly classified into four categories. Despite differing causes, all forms of diabetes share a common feature, pancreatic β-cell dysfunction. This dysfunction results in an insufficient insulin supply, leading to hyperglycemia and subsequent disease onset. Type 1 diabetes (T1D) Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic β-cells, resulting in complete or near-complete insulin deficiency. This condition typically manifests in childhood or adolescence but can occur at any age22). Its pathogenesis involves the presentation of autoantigens by antigen-presenting cells, leading to T-cell activation. Activated T-cells release pro-inflammatory cytokines that destroy β-cells, resulting in absolute insulin deficiency. Patients with T1D require lifelong insulin therapy. Type 2 diabetes (T2D) T2D accounts for approximately 90-95% of diabetes cases worldwide. It is characterized by a combination of insulin resistance due to metabolic abnormal obesity and β-cell dysfunction, leading to relative 3 Iida H, Watada H: Insights into pancreatic β-cell dysfunction and diabetes pathogenesis insulin deficiency. Genetic and environmental factors contribute to its development, and while it predominantly occurs in adults, its incidence among younger populations is increasing23). In patients with T2D, β-cell dysfunction is evident from the early stages of the disease and progressively worsens over time. According to the UK Prospective Diabetes Study (UKPDS), β-cell function in patients with T2D is already reduced by approximately 50% at diagnosis and declines by approximately 5% annually thereafter24). These data suggest that β-cell dysfunction begins approximately a decade prior to the clinical onset of T2D. Cross-sectional studies in Japanese patients with T2D also reported a significant and sustained decline in β-cell function, as indicated by C-peptide levels25, 26). Chronic exposure to hyperglycemia suppresses β-cell function and reduces insulin biosynthesis and secretion while promoting apoptosis. Similarly, prolonged exposure to free fatty acids induces β-cell dysfunction through multifaceted mechanisms. Together, these factors exacerbate β-cell dysfunction known as glucolipotoxicity27). Other types of diabetes Mutations in regions of the insulin gene involved in transcription and translation, or those responsible for disulfide bond formation, can lead to the production of abnormal insulin, which exerts cytotoxic effects on pancreatic β-cells. These mutations impede proper insulin folding, retain misfolded variants in the ER, and induce ER stress and β-cell apoptosis. Additionally, genetic mutations in factors involved in β-cell differentiation, insulin biosynthesis, and insulin secretion can also lead to diabetes. These mechanisms underlie neonatal diabetes diagnosed within the first 12 months of life, mutant INS geneinduced diabetes of youth (MIDY), typically manifesting in childhood, and maturity-onset diabetes of the young (MODY), often developing during adolescence28). MODY is classified into several types based on the causative gene. A genetic abnormality in GK, rate-limiting enzyme of glycolysis, causes MODY 2. Similarly, a genetic abnormality in pancreatic and duodenal homeobox 1 (PDX1), which plays a critical role in pancreatic islet development, is associated with MODY 4, while a genetic abnormality in neurogenic differentiation 1 (NeuroD1) is known to cause MODY 6. Many cases of MIDY and MODY require insulin therapy, however, MODY 1 4 and MODY 3, caused by mutations in the transcription factors hepatocyte nuclear factor 4α (HNF4A) and 1α (HNF1A), respectively, can often improve insulin secretion with sulfonylurea treatment. MODY 2 can sometimes achieve good blood glucose control through lifestyle modifications. Therefore, accurate diagnosis is essential29). Other types of diabetes include those associated with endocrine disorders, such as Cushing’s syndrome, diabetes induced by hyperglycemia-causing drugs, such as steroids, and pancreatogenic diabetes due to pancreatic resection, as in cases of pancreatic cancer. Gestational diabetes mellitus (GDM) Gestational diabetes mellitus (GDM) is commonly defined as hyperglycemia diagnosed or first occurring during pregnancy30). In normal pregnancy, circulating levels of placental hormones, including human placental growth hormone (HPGH), corticotropin-releasing hormone (CRH), human placental lactogen (HPL), prolactin, estrogen, and progesterone, increase and induce insulin resistance. Among these, HPGH, which has a structure similar to pituitary growth hormone, plays a critical role in metabolic adaptations to ensure fetal nutrition. HPGH alters insulin receptor function through inhibiting PI3K activity and preventing the downstream of insulin signaling, which contributes to increased insulin resistance31). As maternal insulin resistance increases, postprandial glucose and free fatty acid levels increase, ensuring an adequate glucose supply for fetal growth. In normal pregnancies, maternal insulin secretion increases to maintain normoglycemia. Failure to adapt to these hormonal changes underlies GDM pathophysiology. Molecular mechanisms of pancreatic β-cell dysfunction Oxidative stress and mitochondrial dysfunction Using glucose-derived metabolites, mitochondria produce ATP by consuming oxygen and produces reactive oxygen species (ROS) as byproducts. Oxidative stress occurs when ROS production surpasses the cellular antioxidant defense system, leading to β-cell apoptosis. Chronic hyperglycemia and elevated fatty acid levels alter mitochondrial number, inner membrane protein content, and Juntendo Medical Journal, 2025 morphology, releasing apoptotic factors. Longchain fatty acids (FFA) also generate hydrogen peroxide (H2O2) via peroxisomal β-oxidation32). Accumulated H2O2 induces oxidative stress in βcells, causing mitochondrial DNA damage and mitochondrial fragmentation33). Endoplasmic reticulum (ER) stress Excessive proinsulin biosynthesis due to increased insulin demand overwhelms the ER’s protein folding capacity, and mutations in proinsulin disrupt disulfide bond formation34). Intracellular redox imbalances also hinder proper disulfide pairing. Cytokines and fatty acids reduce ER calcium levels, impairing chaperone functions, leading to misfolded proinsulin accumulation and impaired insulin synthesis and secretion35). This is termed ER stress. To counter ER stress, the unfolded protein response (UPR) is activated and mediated by IRE1, PERK, and ATF636). •P  ERK pathway: Reduces ER protein load by phosphorylating eIF2α to suppress protein translation. • I RE1 pathway: Activates endoribonuclease activity via autophosphorylation, causing unconventional splicing of XBP1 mRNA, upregulating ER chaperones, lipid biosynthesis enzymes, and ER-associated degradation (ERAD) genes. •A  TF6 pathway: Transports to the Golgi apparatus upon release from BiP, acting as a transcriptional activator for genes maintaining ER homeostasis and degrading unfolded proteins. These pathways aim to restore ER homeostasis by reducing protein translation, enhancing folding capacity, and degrading misfolded proteins. However, failure of these mechanisms triggers cell death. Impaired autophagy Autophagy is a highly conserved process in eukaryotic cells that maintains cellular homeostasis by degrading and recycling cellular components and damaged organelles37). Accumulation of ubiquitinated proteins and damaged mitochondria has been observed in the pancreatic β-cells of autophagy-deficient mice38, 39). In addition, impaired autophagy in pancreatic β-cells has been linked to increased vulnerability of β-cells to the cytotoxic effects of deposited amyloid, particularly human islet amyloid polypeptide (hIAPP), which contrib- utes to the progression of β-cell failure40). In fact, impaired autophagy has been observed in the β-cells of patients with T2D41) and amyloid deposition in pancreatic islets is found in approximately 90% of these patients42). High levels of free fatty acids and glucose further inhibit autophagic and lysosomal functions43, 44), causing the development of T2D. Inflammation In T1D, pancreatic β-cells are targeted and destroyed by islet antigen-specific T-cells via inflammatory cytokines, resulting in absolute insulin deficiency45). Chronic risk factors for T2D, such as overweight, obesity, unhealthy diet, and physical inactivity, have been reported to induce inflammatory pathways over time46). Inflammation is currently recognized as a common pathological condition in both T1D and T2D. Free fatty acids activate inflammatory pathways directly or indirectly via oxidative or ER stress. For example, palmitic acid induces the production of pro-inflammatory cytokines (IL-1β, IL-6, and IL-8), causing inflammatory cell damage47, 48). Interactions between β-cells and immune cells promote the recruitment of M1 macrophages, further amplifying inflammatory responses49). Interaction between stress pathways The multiple stress pathways described above act simultaneously or synergistically, forming a feedforward mechanism that exacerbates glucolipotoxicity and β-cell dysfunction. ROS generation from oxidative stress depletes ER calcium stores, thereby triggering ER stress50). ER stress amplifies inflammatory responses by inducing the expression of inflammatory genes51). These mechanisms are summarized in Figure 1. Conclusion This review summarizes current knowledge on β-cell dysfunction in diabetes. Evidence shows that loss of functional β-cell mass is central to all diabetes types. No therapies currently restore functional β-cell mass. Reducing β-cell burden is the most effective strategy for preserving β-cell mass, so diabetes management should focus on alleviating β-cell stress52, 53). Effective treatment includes lifestyle modifications, especially dietary adjustments 5 Iida H, Watada H: Insights into pancreatic β-cell dysfunction and diabetes pathogenesis Figure 1 Molecular mechanisms of pancreatic β-cell dysfunction caused from glucolipotoxicity A prolonged elevation in free fatty acid (FFA) levels together with high glucose levels trigger stress responses in pancreatic β-cells. These responses include endoplasmic reticulum (ER) stress, oxidative stress marked by excessive reactive oxygen species (ROS) production, mitochondrial dysfunction, inflammation, and disruptions in autophagic processes. Interactions among these pathways can create feed-forward mechanisms, intensifying glucolipotoxic stress. Ultimately, these combined effects lead to β-cell dysfunction, cell death (apoptosis), and potentially a loss of their specialized function (dedifferentiation). (Modified quote from Ref. 27). to limit calorie, carbohydrate, and fat intake, and regular physical activity to promote an active lifestyle54, 55). Pharmacological interventions alone do not address the root causes of diabetes and may increase adverse events due to excessive medication reliance. Understanding β-cell dysfunction mechanisms and the impact of lifestyle changes on β-cell health can motivate patients to adopt proactive diabetes prevention and management strategies. Continued research is essential for developing novel therapies and improving outcomes for those at risk or living with diabetes. Acknowledgments Not applicable. Funding No funding was received. Author contributions HI wrote the draft. HW reviewed the manuscript. All authors read and approved the manuscripts. 6 Conflicts of interest statement The authors declare that there are no conflicts of interest. References 1) Magliano DJ, Boyko EJ: Idf diabetes atlas, 10th edition. Brussels: International Diabetes Federation International Diabetes Federation, 2021. 2) Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature, 2001; 414: 782-787. 3) Cui J, Liu Y, Li Y, Xu F, Liu Y: Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective. Front Cardiovasc Med, 2021; 8: 644189. 4) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234. 5) Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB: Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract, 2012; 66: 1147-1157. 6) Centers for Disease Control and Prevention: National Diabetes Statistics Report. https://www.cdc.gov/ diabetes/php/data-research/index.html. (Accessed Dec 12, 2024) 7) Japan Diabetes Clinical Data Management Study Group: Juntendo Medical Journal, 2025 Basic Aggregated Data. http://jddm.jp/public-information/index-2022/(Accessed Dec 12, 2024) 8) Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ: Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care, 2013; 36: 1789-1796. 9) Da Silva Xavier G: The Cells of the Islets of Langerhans. J Clin Med, 2018; 7: 54. 10) Ichise M, Harris PE: Imaging of beta-cell mass and function. J Nucl Med, 2010; 51: 1001-1004. 11) Tiedge M: Inside the pancreas: progress and challenges of human beta cell mass quantification. Diabetologia, 2014; 57: 856-859. 12) Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC: β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care, 2013; 36: 111-117. 13) Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC: Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab, 2008; 10 Suppl 4: 32-42. 14) Fukushima M, Suzuki H, Seino Y: Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract, 2004; 66 Suppl 1: S37-43. 15) Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased betacell apoptosis in humans with type 2 diabetes. Diabetes, 2003; 52: 102-110. 16) Ataie-Ashtiani S, Forbes B: A Review of the Biosynthesis and Structural Implications of Insulin Gene Mutations Linked to Human Disease. Cells, 2023; 12: 1008. 17) Vasiljević J, Torkko JM, Knoch KP, Solimena M: The making of insulin in health and disease. Diabetologia, 2020; 63: 1981-1989. 18) Liu M, Huang Y, Xu X, et al: Normal and defective pathways in biogenesis and maintenance of the insulin storage pool. J Clin Invest, 2021; 131: e142240. 19) Omar-Hmeadi M, Idevall-Hagren O: Insulin granule biogenesis and exocytosis. Cell Mol Life Sci, 2021; 78: 1957-1970. 20) Germanos M, Gao A, Taper M, Yau B, Kebede MA: Inside the Insulin Secretory Granule. Metabolites, 2021; 11. 21) Campbell JE, Newgard CB: Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol, 2021; 22: 142-158. 22) Katsarou A, Gudbjörnsdottir S, Rawshani A, et al: Type 1 diabetes mellitus. Nat Rev Dis Primers, 2017; 3: 17016. 23) Lu X, Xie Q, Pan X, et al: Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther, 2024; 9: 262. 24) U.K. prospective diabetes study 16: Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes, 1995; 44: 1249-1258. 25) Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, Itoh H: Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis. Endocr J, 2012; 59: 187-195. 26) Funakoshi S, Fujimoto S, Hamasaki A, et al: Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic expo- sure. Diabetes Res Clin Pract, 2008; 82: 353-358. 27) Lytrivi M, Castell AL, Poitout V, Cnop M: Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. J Mol Biol, 2020; 432: 1514-1534. 28) Støy J, De Franco E, Ye H, Park SY, Bell GI, Hattersley AT: In celebration of a century with insulin - Update of insulin gene mutations in diabetes. Mol Metab, 2021; 52: 101280. 29) Delvecchio M, Pastore C, Giordano P: Treatment Options for MODY Patients: A Systematic Review of Literature. Diabetes Ther, 2020; 11: 1667-1685. 30) McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P: Gestational diabetes mellitus. Nat Rev Dis Primers, 2019; 5: 47. 31) Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE: Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care, 2007; 30 Suppl 2: S112-119. 32) Elsner M, Gehrmann W, Lenzen S: Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes, 2011; 60: 200-208. 33) Molina AJ, Wikstrom JD, Stiles L, et al: Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. Diabetes, 2009; 58: 2303-2315. 34) Arunagiri A, Haataja L, Pottekat A, et al: Proinsulin misfolding is an early event in the progression to type 2 diabetes. Elife, 2019; 8. 35) Iida H, Kono T, Lee CC, et al: SERCA2 regulates proinsulin processing and processing enzyme maturation in pancreatic beta cells. Diabetologia, 2023; 66: 2042-2061. 36) Liu M, Weiss MA, Arunagiri A, et al: Biosynthesis, structure, and folding of the insulin precursor protein. Diabetes Obes Metab, 2018; 20 Suppl 2: 28-50. 37) Yamamoto H, Zhang S, Mizushima N: Autophagy genes in biology and disease. Nat Rev Genet, 2023; 24: 382-400. 38) Ebato C, Uchida T, Arakawa M, et al: Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab, 2008; 8: 325-332. 39) Jung HS, Chung KW, Won Kim J, et al: Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab, 2008; 8: 318-324. 40) Shigihara N, Fukunaka A, Hara A, et al: Human IAPPinduced pancreatic β cell toxicity and its regulation by autophagy. J Clin Invest, 2014; 124: 3634-3644. 41) Masini M, Bugliani M, Lupi R, et al: Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia, 2009; 52: 1083-1086. 42) O’Brien TD, Butler PC, Westermark P, Johnson KH: Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol, 1993; 30: 317-332. 43) Las G, Serada SB, Wikstrom JD, Twig G, Shirihai OS: Fatty acids suppress autophagic turnover in β-cells. J Biol Chem, 2011; 286: 42534-42544. 44) Mir SU, George NM, Zahoor L, Harms R, Guinn Z, Sarvetnick NE: Inhibition of autophagic turnover in β-cells by fatty acids and glucose leads to apoptotic cell death. J Biol Chem, 2015; 290: 6071-6085. 45) Yue M, He X, Min X, et al: The role of islet autoantigen-specific T cells in the onset and treatment of type 1 diabetes mellitus. Front Immunol, 2024; 15: 1462384. 46) Tsalamandris S, Antonopoulos AS, Oikonomou E, et al: 7 Iida H, Watada H: Insights into pancreatic β-cell dysfunction and diabetes pathogenesis The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol, 2019; 14: 50-59. 47) Böni-Schnetzler M, Boller S, Debray S, et al: Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology, 2009; 150: 5218-5229. 48) Igoillo-Esteve M, Marselli L, Cunha DA, et al: Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia, 2010; 53: 13951405. 49) Eguchi K, Manabe I, Oishi-Tanaka Y, et al: Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab, 2012; 15: 518-533. 50) Hara T, Mahadevan J, Kanekura K, Hara M, Lu S, Urano F: Calcium efflux from the endoplasmic reticulum leads to β-cell death. Endocrinology, 2014; 155: 758-768. 8 51) Meyerovich K, Ortis F, Allagnat F, Cardozo AK: Endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. J Mol Endocrinol, 2016; 57: R1-r17. 52) DeFronzo RA, Abdul-Ghani MA: Preservation of βcell function: the key to diabetes prevention. J Clin Endocrinol Metab, 2011; 96: 2354-2366. 53) de Koning EJ, Bonner-Weir S, Rabelink TJ: Preservation of beta-cell function by targeting beta-cell mass. Trends Pharmacol Sci, 2008; 29: 218-227. 54) The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25: 21652171. 55) Zhang Y, Yang Y, Huang Q, Zhang Q, Li M, Wu Y: The effectiveness of lifestyle interventions for diabetes remission on patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Worldviews Evid Based Nurs, 2023; 20: 64-78.